Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Great Bay Bio Closes $10 Million Funding for AI CMC Biologic Services

publication date: Dec 31, 2021

Great Bay Bio of Hong Kong closed a $10 million Series A funding for its AI-enabled CMC bioprocessing of biologic drug candidates. The company says its technology addresses the problems of high failure rates, long development timelines and high costs. GBB has accumulated large amounts of bioprocessing development data from its 3100 square meter CMC facility. It is creating an intelligent centralized database, using deep learning to create a next-gen AI-enabled bioprocessing ecosystem. FutureX Capital was the last investor to join the financing. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital